US HB7071 | 2019-2020 | 116th Congress
Status
Spectrum: Bipartisan Bill
Status: Introduced on June 1 2020 - 25% progression, died in committee
Action: 2020-06-01 - Referred to the House Committee on Energy and Commerce.
Pending: House Energy And Commerce Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on June 1 2020 - 25% progression, died in committee
Action: 2020-06-01 - Referred to the House Committee on Energy and Commerce.
Pending: House Energy And Commerce Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Establishes a grant program, as well as a new center within the Food and Drug Administration (FDA), to facilitate access to investigational therapies for neurodegenerative diseases such as amyotrophic lateral sclerosis (i.e., ALS, also known as Lou Gehrig's disease, a progressive and fatal disease). Specifically, the Department of Health and Human Services (HHS) must award grants for the provision of investigational drugs for ALS and other rapidly progressing neurodegenerative diseases through an expanded access (i.e., compassionate use) program. HHS may award these grants to (1) a small business that is the sponsor of an investigational new drug application, or (2) a participating clinical trial site for such a sponsor. Additionally, HHS must establish within the FDA a Center of Excellence for Neurodegenerative Diseases. The center shall have duties and authorities similar to those of the FDA's Oncology Center of Excellence, which helps expedite the development of medical products and assists providers in requesting access to investigational drugs.
Title
Accelerating Access to Critical Therapies for ALS Act
Sponsors
History
Date | Chamber | Action |
---|---|---|
2020-06-01 | House | Referred to the House Committee on Energy and Commerce. |
2020-06-01 | House | Introduced in House |
Same As/Similar To
SB4867 (Related) 2020-10-26 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Subjects
Congressional oversight
Drug safety, medical device, and laboratory regulation
Drug therapy
Health
Health care coverage and access
Health programs administration and funding
Health promotion and preventive care
Neurological disorders
Prescription drugs
Drug safety, medical device, and laboratory regulation
Drug therapy
Health
Health care coverage and access
Health programs administration and funding
Health promotion and preventive care
Neurological disorders
Prescription drugs
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/116th-congress/house-bill/7071/all-info |
Text | https://www.congress.gov/116/bills/hr7071/BILLS-116hr7071ih.pdf |